Gilead Sciences · 1 month ago
Director, Value Access & Strategy
United States - California - Santa Monica
Full-time
Hybrid
Director/Executive
$206K/yr - $266K/yr
10+ years expGilead Sciences is dedicated to curing cancer and advancing therapies for various diseases. The Director of Value Access & Strategy will play a critical role in developing global market access strategies for key CAR T-cell therapy launches, collaborating with multiple teams to ensure effective access and reimbursement strategies.
BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Key Market Access representative and lead in the Global Brand Team and Join-GBT for anito-cel
In the Value Access Sub-Team, you will be partnering with the Global and Regional functions of Value Access, HEOR/RWE and commercial to ensure seamless execution of the Access Strategy
Analyze future market access trends and competitor entry and advise the GBT/PT on access-relevant endpoints, study designs, and magnitude of effect to be targeted to achieve reimbursement. The focus will be on Kite’s major markets of US, Australia, Canada, EU-5 (ACE-7), and Japan. You will inform development plans to ensure that Kite pursues evidence generation plans that are meeting payer needs and ultimately, Kite’s commercial ambitions
Provide input into clinical development programs to capture value, align to what is meaningful to patients, support a differentiated target product profile (TPP), and ensure the right evidence is collected to support future reimbursement and pricing negotiations
Accountable for the market access and payer perspective to be reflected in cross functional strategies (product development, medical affairs, regulatory affairs, commercial)
Partner with Health Economics Outcomes Research (HEOR), Real-World Evidence (RWE), and Global Marketing to ensure meaningful target product profiles are developed and evidence plans are optimized to support reimbursement
Identify global HEOR evidence requirements and gaps; coordinate with HEOR to develop studies, models, and resources to support value demonstration and product differentiation for assigned indication(s)
Qualification
Required
12+ Years with BS/BA
10+ Years with MS/MA or MBA
Preferred
Previous experience supporting product launches, ideally in oncology
Demonstrated experience in healthcare environment, preferably pharmaceutical industry, or related consulting services
Extensive understanding of the global hematology / multiple myeloma market access landscape, the business of cell therapy, and healthcare system dynamics
Detailed knowledge of payer systems, pricing and reimbursement mechanisms, decision-makers, and payer stakeholder behavior for relevant markets (US, EU5, Japan)
Knowledge of HTA assessments including value frameworks utilized, methodologies, trends, and drivers in relevant markets
Ability to guide the development plan and lead inputs based on payer requirements / market access trends
Excellent communication skills and experience in presenting at senior committees
Ability to collaborate successfully and cooperatively with colleagues across multiple cultures and time-zones
Demonstrated leadership in cross-functional teams
Benefits
Discretionary annual bonus
Discretionary stock-based long-term incentives (eligibility may vary based on role)
Paid time off
Company-sponsored medical, dental, vision, and life insurance plans
Company
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
10001+ employees
H1B Sponsorship
Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (269)
2024 (241)
2023 (222)
2022 (208)
2021 (235)
2020 (187)
Funding
Current Stage
Public CompanyTotal Funding
$4.41BKey Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B
Leadership Team
Keeley Wettan
Senior Vice President, Legal
Patrick Loerch
Senior Vice President, Clinical Data Science
Recent News
2026-01-16
FierceBiotech
2026-01-16
Company data provided by crunchbase